INTRODUCTION
============

α1-antitrypsin (AAT) exhibits anti-inflammatory activity and its deficiency causes respiratory and inflammatory disorders ([@B1][@B2][@B3][@B4][@B5][@B6][@B7][@B8]). AAT directly blocks serine proteinases activating interleukin (IL)-1 cytokine family, IL-8, IL-32, and tumor necrosis factor (TNF)-α ([@B9][@B10][@B11]). IL-32, originally discovered as a natural killer cell transcript 4 (NK4) and renamed as IL-32 (also known as TNFα-inducing factor (TAIF) in databank), induces various inflammatory cytokines via NF-κB and p38MAPK signaling ([@B10][@B12][@B13][@B14][@B15][@B16][@B17][@B18]). IL-32α-ligand affinity chromatography lead to isolation of neutrophil proteinase 3 (PR3) from human urine ([@B9]). Mature PR3 specifically binds to IL-32 and cleaves it. The suppression of IL-32 expression by AAT increased survival in an allogeneic bone marrow (BM) transplantation mouse model ([@B19]). Unlike other cytokines possessing specific membrane receptors, IL-32 utilizes membrane PR3 to induce inflammation. Therefore, this study aimed to investigate the inhibitory activity of AAT on IL-32-induced inflammation in mouse BM cells.

MATERIALS AND METHODS
=====================

Primary mouse BM cells were isolated from 6-week-old female C57BL/6 mice as described previously ([@B20]), seeded on a 96-well plate at a density of 1×10^6^/0.2 mL, and then stimulated with 100 ng/mL LPS (Sigma-Aldrich, St. Louis, MO, USA), TNFα, IL-32γ, and IL-1α (YbdYbiotech, Seoul Korea) as indicated at the bottom. The animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Konkuk University. IL-32γ-induced NF-κB and p38MAPK phosphorylation in BM cells isolated from 6-week-old C57BL/6 mice was examined using anti-phospho antibodies (Cell Signaling Technology, Beverly, MA, USA). Recombinant PR3-Fc was expressed as described previously ([@B21]), and then was used in IL-32γ binding assay. A 96-well plate was coated with PR3-Fc (1 µg/mL) overnight and blocked with 3% BSA for 2 h. IL-32γ was added at the concentration indicated at the bottom, and was detected by rabbit anti-IL-32γ antibody ([@B22]). AAT-Fc was pre-incubated with PR3-Fc-coated 96-well plate at a concentration indicated at the bottom, and then its reaction with IL-32γ was detected by rabbit anti-IL-32γ antibody.

RESULTS AND DISCUSSION
======================

Here, the anti-inflammatory activity of AAT was investigated in BM cells. Primary mouse BM cells were stimulated with LPS, TNFα, IL-32γ, and IL-1α because they trigger common inflammatory pathways, such as NF-κB and p38MAPK, although they possess a specific receptor. IL-1α induced IL-6 at the highest level, whereas TNFα induced IL-6 at the lowest level, as compared to the induction level of other stimuli ([Fig. 1A](#F1){ref-type="fig"}). Mouse BM cells were pre-incubated with recombinant AAT-Fc and then triggered with the same stimuli ([Fig. 1B](#F1){ref-type="fig"}). Interestingly, AAT-Fc specifically suppressed IL-32γ-induced IL-6 expression, while AAT-Fc failed to inhibit IL-6 expression induced by other stimuli ([Fig. 1B](#F1){ref-type="fig"}). This data is presented for the first time with direct evidence that AAT-Fc inhibits the inflammatory activity of IL-32 in mouse BM cells. In addition, AAT-Fc experiments were performed by pretreating mice for 48 h prior to isolating BM cells. As shown in [Fig. 1E](#F1){ref-type="fig"}, IL-32γ-induced IL-6 expression was further decreased in AAT-Fc-pretreated mice, but IL-6 expression induced by other stimuli was not inhibited ([Fig. 1C, D, and F](#F1){ref-type="fig"}).

Next, NF-κB and p38MAPK signaling were assessed in the mouse BM cells after IL-32γ stimulation. The phosphorylation of NF-κB and p38MAPK was increased by IL-32γ treatment ([Fig. 2A](#F2){ref-type="fig"}), while it was significantly suppressed in the BM cells from AAT-Fc-administered mice ([Fig. 2B](#F2){ref-type="fig"}). In addition, recombinant PR3-Fc was expressed in Chinese Hamster Ovary cells by using the open reading frame of PR3 fused to human Fc as described previously ([@B21]). The PR3-Fc protein was used to indicate IL-32γ binding to PR3. IL-32γ binds to PR3-Fc in 1 nM range with a high affinity, since approximately 30 kDa IL-32γ exhibits a specific binding at 30 ng/mL ([Fig. 2C](#F2){ref-type="fig"}). The specific IL-32γ binding to PR3-Fc was abrogated by AAT-Fc in a dose-dependent manner ([Fig. 2D](#F2){ref-type="fig"}).

These data suggest that AAT-Fc blocks IL-32-induced inflammation in BM cells by competing with IL-32γ to bind on membrane PR3 and increases the survival of allogeneic BM transplantation mouse model ([Fig. 2E](#F2){ref-type="fig"}). Unlike other cytokines with specific membrane receptors, IL-32 utilizes membrane PR3 to induce inflammation. This may explain the specific inhibitory activity of AAT on IL-32-induced inflammation in patients with allogeneic BM transplantation. The present study illustrates the function of IL-32 in BM inflammation that is specifically suppressed by AAT-Fc. Further investigation on IL-32-mediated inflammation in human BM transplantation will help understand the causative factor in GvHD.
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![The anti-inflammatory effect of recombinant AAT-Fc in mouse BM cells. (A) IL-6 level in the supernatant of mouse BM cells was measured by sandwich ELISA (R&D Systems, Minneapolis MN). (B) The induction of IL-6 by different stimuli was measured without AAT-Fc (open bar) or with pre-incubation of AAT-Fc (closed bar, 2 µg/mL) for 3 h. (C) LPS-, (D) TNFα-, (E) IL-32γ-, and (F) IL-1α-mediated IL-6 level in the supernatant of BM cells isolated from the mice treated with AAT-Fc for 48 h was compared to that in the supernatant of BM cells isolated from the untreated control mice. Data in A are comparisons between untreated control and stimulated mice. Data in B are comparisons between RPMI control and AAT-Fc pre-incubated cells. Data in E are comparisons between BM cells isolated from untreated mice and BM cells isolated from mice treated with AAT-Fc (2 mg/kg) for 48 h. Mean±SEM; ^\*^p\<0.05; ^\#^p\<0.001 from three replicates. Representative data from 1 of 3 independent experiments are shown.](in-17-116-g001){#F1}

![Suppression of inflammatory signaling in recombinant AAT-Fc-pretreated mouse BM cells, AAT-Fc competing with IL-32γ binding to PR3-Fc, and the dogma of AAT anti-inflammatory activity on IL-32-induced inflammation in BM transplantation. (A) The phosphorylation of NF-κB and p38MAPK by IL-32γ in BM cells from 6-week-old C57BL/6 mice was assessed using anti-phospho antibodies. (B) Similar experiments were performed by injecting AAT-Fc (2 mg/kg) into mice for 48 h prior to isolating BM cells. (C) Recombinant PR3-Fc was used for IL-32γ binding assay. IL-32γ was added at the concentration indicated on the bottom, and IL-32γ binds to PR3-Fc in a dose dependent manner. (D) The binding of IL-32γ was blocked with PR3-Fc in a dose dependent manner. Data in C are comparisons between control blank and IL-32γ-treated cells. Data in D are comparisons between control without AAT-Fc and with AAT-Fc. Mean±SEM; ^\*^p\<0.05; ^\*\*^p\<0.01; ^\#^p\<0.001 from three replicates. Representative data from 1 of 4 independent experiments are shown. (C) Schematic representation of AAT-Fc suppression on IL-32-mediated inflammation in BM transplantation. Allogeneic BM transplantation induces different pro-inflammatory cytokines, such as IL-32, TNFα, IL-1α, and IL-6, resulting in immune reaction causing GvHD and death, while the specific IL-32 blockade AAT-Fc reduces immune reaction increasing survival.](in-17-116-g002){#F2}
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